API SUPPLIERS

API Suppliers

0

US DMFs Filed

0

CEP/COS Certifications

0

JDMFs Filed

0

EU WC

0

Listed Suppliers

0

API REF. PRICE (USD / KG)

0

API Market Place

0

INTERMEDIATES

0

DOSSIERS // FDF

USA (Orange Book)

0

Europe

0

Canada

0

Australia

0

South Africa

0

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

FDF Market Place

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

0

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Full Screen View

VLP Therapeutics

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

VLP Therapeutics Raises $21M Series A-1 For Cancer Treatment Vaccine, Infectious Diseases Vaccine R&D

Details:

With this funding, VLPT aims to further accelerate the research and development of a cancer treatment vaccine as well as prophylactic vaccines including VLPM01, against malaria, dengue, etc. and move into clinical trials at the earliest date possible.

Lead Product(s): VLPM01

Therapeutic Area: Infections and Infectious Diseases Product Name: VLPM01

Highest Development Status: Phase IProduct Type: Vaccine

Partner/Sponsor/Collaborator: Nobelpharma

Deal Size: $21.0 million Upfront Cash: Undisclosed

Deal Type: Series A Financing December 27, 2021

ASK
US